Tagged: cdmo
8 results
Made Scientific
Made Scientific is a Princeton, New Jersey-based contract development and manufacturing organization (CDMO) focused exclusively on cell therapies. Formerly BioCentriq, it was rebranded in March 2025 and is backed by South Korea's GC Corporation. The company runs a 60,000 sq. ft. GMP facility with five ISO 7 / Grade B cleanrooms, offering process and analytical development, GMP manufacturing of autologous and allogeneic products, aseptic fill and finish, QC release testing, regulatory consulting, and workforce training, taking cell therapy programs from preclinical development through commercial supply.
Sware
Sware is a Boston-based software company that modernizes GxP validation for life sciences. Its cloud-native Res_Q platform and developer-focused GxPNext product use AI and a decade of regulated validation knowledge to automate the computer system validation (CSV) work that the FDA and other regulators require - helping pharmaceutical, biotech, medical device and CDMO teams cut validation time and cost while staying audit-ready. Formerly Boston Technology Research (BTR), the company rebranded to Sware in 2022 and has raised roughly $26-27M to date.
Aizon
Aizon is a San Francisco-based software company that builds AI solutions exclusively for pharmaceutical and biotech manufacturing. Its GxP-compliant platform ingests structured and unstructured production data to run electronic batch records, real-time process monitoring, predictive analytics and, increasingly, agentic AI that helps quality and operations teams cut deviations, improve yield and speed batch review. Formerly known as Bigfinite and founded in 2014, the company has raised roughly $45 million and counts pharma names such as Grifols and Curia among its users.
Syed T. Husain
Syed T. Husain is the Chairman and CEO of Made Scientific, a Princeton, New Jersey cell therapy contract development and manufacturing organization (CDMO) that he relaunched in 2025 out of the former BioCentriq. Backed by GC Corporation, the company runs a 60,000-square-foot GMP facility built to move autologous and allogeneic cell therapies from clinical batches to commercial supply. A chemical engineer by training who started on the manufacturing floor at Wyeth and Pfizer, Husain spent more than two decades in CDMO leadership at Lonza, Alcami, Emergent BioSolutions, and Resilience before taking the top job. He named the rebranded company MADE for Manufacturing and Development Excellence.
Cromatic
Cromatic is an AI-native platform for life-science R&D outsourcing and revenue operations. It runs a curated marketplace connecting biotech and pharma companies with vetted Contract Research Organizations (CROs) and Contract Development and Manufacturing Organizations (CDMOs), then layers on vendor discovery, project tracking, data storage, collaboration, contracting, and milestone payments so scientists can outsource complex research without stitching together spreadsheets, email threads, and word-of-mouth referrals. Founded in 2022 by Stanford geneticist Ann Lin and former Meta engineer Anne Chen, the company raised a $5.3M oversubscribed seed round in November 2023 and manages tens of millions of dollars in research budgets.
Christian Cobaugh
Christian Cobaugh is a molecular biologist turned biotech operator who has spent more than 15 years at the frontier of genetic medicines. In January 2026 he became CEO of Alloy Genetic Medicines, the nucleic-acid division of Alloy Therapeutics, where he leads work on the AntiClastic cyclic nucleic acid platform for ASOs, siRNA, and other RNA therapeutics. He is best known for founding Vernal Biosciences, an mRNA contract manufacturer he built in Colchester, Vermont, on the premise that everyone who needs mRNA should be able to get it. Before Vernal he was the first scientist in the Alexion-Moderna mRNA partnership and held discovery, development, and manufacturing roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics.
I Peace, Inc.
I Peace, Inc. is a Palo Alto- and Kyoto-based biotech that mass-manufactures clinical-grade induced pluripotent stem cells (iPSCs) using a proprietary automated, closed-cassette platform. Founded in 2015 by Koji Tanabe - a co-author of the world's first human iPSC paper from Shinya Yamanaka's Nobel Prize-winning lab - the company operates as a CDMO supplying GMP-grade iPSCs to pharmaceutical companies, biotechs, and research institutions, and offers personal iPSC banking and longevity services that aim to make cell therapy affordable and accessible.
Nventric, Inc.
Nventric, Inc. is a medical device company and contract development and manufacturing organization (CDMO) headquartered in Arcadia, California, with operations in Seoul, South Korea. Founded in 2019 by engineers with backgrounds at Abbott Vascular and Johnson & Johnson, Nventric designs and builds minimally invasive vascular devices - covering neurovascular, coronary, and electrophysiology applications - from concept through scalable, ISO 13485-certified manufacturing. Its own-branded neurovascular line, including the ULTRIVA stent retriever and EVOGLIDE distal access catheter, targets acute ischemic stroke, while its OEM/CDMO services help device companies move products from prototype to commercialization.